List of Gavreto drug patents

Gavreto is owned by Genentech Inc.

Gavreto contains Pralsetinib.

Gavreto has a total of 2 drug patents out of which 0 drug patents have expired.

Gavreto was authorised for market use on 04 September, 2020.

Gavreto is available in capsule;oral dosage forms.

Gavreto can be used as treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test, treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate); treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy.

Drug patent challenges can be filed against Gavreto from 2024-09-04.

The generics of Gavreto are possible to be released after 03 April, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10030005 GENENTECH INC Inhibitors of RET
Nov, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273160 GENENTECH INC RET inhibitor for use in treating cancer having a RET alteration
Apr, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 4, 2025
Orphan Drug Exclusivity (ODE) Sep 4, 2027

Drugs and Companies using PRALSETINIB ingredient

NCE-1 date: 2024-09-04

Market Authorisation Date: 04 September, 2020

Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatri...

Dosage: CAPSULE;ORAL

More Information on Dosage

GAVRETO family patents

19

United States

6

Japan

3

Israel

3

China

3

European Union

2

Australia

2

Singapore

2

Brazil

2

Korea, Republic of

2

Chile

2

Canada

1

South Africa

1

Mexico

1

Saudi Arabia

1

Hong Kong

1

Russia

1

Morocco

1

Philippines

1

Costa Rica

1

Argentina

1

Peru

1

Taiwan, Province of China

1

Ecuador

EA

1

EA

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in